- Home
- CISS vs QLGN Comparison
CISS vs QLGN Comparison
Compare CISS & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- QLGN
- Stock Information
- Founded
- CISS 2022
- QLGN 1996
- Country
- CISS Greece
- QLGN United States
- Employees
- CISS N/A
- QLGN N/A
- Industry
- CISS Marine Transportation
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- QLGN Health Care
- Exchange
- CISS Nasdaq
- QLGN Nasdaq
- Market Cap
- CISS 2.4M
- QLGN 2.2M
- IPO Year
- CISS N/A
- QLGN N/A
- Fundamental
- Price
- CISS $3.90
- QLGN $3.48
- Analyst Decision
- CISS
- QLGN
- Analyst Count
- CISS 0
- QLGN 0
- Target Price
- CISS N/A
- QLGN N/A
- AVG Volume (30 Days)
- CISS 62.5K
- QLGN 158.4K
- Earning Date
- CISS 05-27-2025
- QLGN 05-06-2025
- Dividend Yield
- CISS N/A
- QLGN N/A
- EPS Growth
- CISS N/A
- QLGN N/A
- EPS
- CISS N/A
- QLGN N/A
- Revenue
- CISS $42,296,101.00
- QLGN N/A
- Revenue This Year
- CISS N/A
- QLGN N/A
- Revenue Next Year
- CISS N/A
- QLGN N/A
- P/E Ratio
- CISS N/A
- QLGN N/A
- Revenue Growth
- CISS 47.17
- QLGN N/A
- 52 Week Low
- CISS $2.85
- QLGN $2.85
- 52 Week High
- CISS $29.40
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- CISS 50.21
- QLGN 52.85
- Support Level
- CISS $3.20
- QLGN $3.10
- Resistance Level
- CISS $3.58
- QLGN $4.40
- Average True Range (ATR)
- CISS 0.37
- QLGN 0.40
- MACD
- CISS 0.10
- QLGN 0.05
- Stochastic Oscillator
- CISS 70.50
- QLGN 40.32
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.